JP2017532343A - 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物 - Google Patents

駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物 Download PDF

Info

Publication number
JP2017532343A
JP2017532343A JP2017520447A JP2017520447A JP2017532343A JP 2017532343 A JP2017532343 A JP 2017532343A JP 2017520447 A JP2017520447 A JP 2017520447A JP 2017520447 A JP2017520447 A JP 2017520447A JP 2017532343 A JP2017532343 A JP 2017532343A
Authority
JP
Japan
Prior art keywords
heart failure
ejection fraction
neuregulin
nrg
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532343A5 (enExample
Inventor
ズホウ ミングドング
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．, ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2017532343A publication Critical patent/JP2017532343A/ja
Publication of JP2017532343A5 publication Critical patent/JP2017532343A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017520447A 2014-10-17 2015-10-08 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物 Pending JP2017532343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201410550212.7 2014-10-17
PCT/CN2015/091459 WO2016058493A1 (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020139931A Division JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Publications (2)

Publication Number Publication Date
JP2017532343A true JP2017532343A (ja) 2017-11-02
JP2017532343A5 JP2017532343A5 (enExample) 2018-10-18

Family

ID=55746124

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017520447A Pending JP2017532343A (ja) 2014-10-17 2015-10-08 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2020139931A Pending JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2022108771A Pending JP2022153417A (ja) 2014-10-17 2022-07-06 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2024135192A Pending JP2024164068A (ja) 2014-10-17 2024-08-14 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020139931A Pending JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2022108771A Pending JP2022153417A (ja) 2014-10-17 2022-07-06 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2024135192A Pending JP2024164068A (ja) 2014-10-17 2024-08-14 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Country Status (10)

Country Link
US (3) US10561709B2 (enExample)
EP (2) EP3207940B1 (enExample)
JP (4) JP2017532343A (enExample)
KR (2) KR20230159650A (enExample)
CN (3) CN111407882A (enExample)
AU (2) AU2015333335B2 (enExample)
CA (1) CA2963322A1 (enExample)
ES (1) ES2924395T3 (enExample)
RU (1) RU2017116973A (enExample)
WO (1) WO2016058493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP2903632A4 (en) 2012-10-08 2016-07-13 Zensun Shanghai Science And Technology Ltd COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
EP3774859B1 (en) * 2018-04-11 2024-03-13 Salubris Biotherapeutics, Inc. Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014094951A (ja) * 2002-05-24 2014-05-22 Zensun (Shanghai) Science & Technology Ltd 心血管疾患を処置するためのニューレギュリン法および組成物
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
DK0970207T3 (da) 1997-02-10 2009-07-13 Genentech Inc Heregulin-varianter
EP1028735A4 (en) 1997-10-14 2003-08-06 Cenes Pharmaceuticals Inc THERAPEUTIC METHOD COMPRISING THE USE OF NEUREGULIN
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
WO2001064877A2 (en) 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
MXPA02011656A (es) 2000-05-23 2004-07-30 Cenes Pharmaceuticals Inc Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
AU2001290864A1 (en) 2000-09-12 2002-04-02 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Optimized cardiac contraction through differential phosphorylation of myosin
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
MXPA05005653A (es) 2002-11-27 2005-11-23 Artesian Therapeutics Inc Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca.
JP2007505158A (ja) 2003-05-21 2007-03-08 ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
WO2006108208A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
JP2010517023A (ja) 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
MX384378B (es) * 2008-07-17 2025-03-14 Acorda Therapeutics Inc Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
EP2370093A4 (en) 2008-11-28 2012-08-29 Zensun Shanghai Science And Technology Ltd NEUREGULIN AND CARDIAC STEM CELLS
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
WO2010142141A1 (en) 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
ES2637072T3 (es) 2010-03-10 2017-10-10 Cempra Pharmaceuticals, Inc. Formulación parenteral de antibióticos macrólidos
EP2555788B1 (en) 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
CN103327986B (zh) 2010-07-22 2018-05-25 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
EP2903632A4 (en) 2012-10-08 2016-07-13 Zensun Shanghai Science And Technology Ltd COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
JP6568052B2 (ja) 2013-05-22 2019-09-04 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． 心不全を治療するためのニューレグリンの徐放
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014094951A (ja) * 2002-05-24 2014-05-22 Zensun (Shanghai) Science & Technology Ltd 心血管疾患を処置するためのニューレギュリン法および組成物
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Also Published As

Publication number Publication date
EP3207940B1 (en) 2022-06-01
AU2021258063A1 (en) 2021-11-25
CN108064164A (zh) 2018-05-22
EP3207940A4 (en) 2018-06-06
KR20170066440A (ko) 2017-06-14
JP2024164068A (ja) 2024-11-26
US20170232068A1 (en) 2017-08-17
EP4112068A1 (en) 2023-01-04
US20200368317A1 (en) 2020-11-26
CA2963322A1 (en) 2016-04-21
WO2016058493A1 (zh) 2016-04-21
CN105561298A (zh) 2016-05-11
AU2015333335B2 (en) 2021-08-05
RU2017116973A (ru) 2018-11-19
JP2020193217A (ja) 2020-12-03
KR20230159650A (ko) 2023-11-21
AU2021258063B2 (en) 2025-02-27
EP3207940A1 (en) 2017-08-23
KR102603711B1 (ko) 2023-11-20
JP2022153417A (ja) 2022-10-12
ES2924395T3 (es) 2022-10-06
AU2015333335A1 (en) 2017-04-20
US20220354928A1 (en) 2022-11-10
RU2017116973A3 (enExample) 2019-05-06
CN111407882A (zh) 2020-07-14
US10561709B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
AU2021258063B2 (en) Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure
JP7761964B2 (ja) 心不全の治療用組成物
US12208158B2 (en) Extended release of neuregulin for treating heart failure
EP3199174B1 (en) Uses of neuregulin in preventing, treating or delaying ventricular arrhythmia
CN110835368A (zh) 神经调节蛋白多肽片段及其用途
HK1241737A1 (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
HK1241737B (en) Compositions of a neuregulin for preventing, treating or delaying preserved ejection fraction cardiac failure
JP2022516199A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200428

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200821

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200915

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200915

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20201104

C032 Notice prior to dismissal

Free format text: JAPANESE INTERMEDIATE CODE: C032

Effective date: 20201201

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201201